Form 4: C4 Therapeutics Director Owen Hughes Granted 35,500 Stock Options

C4 Therapeutics, Inc. Director Owen Hughes was granted 35,500 stock options with an exercise price of $1.44, vesting by June 2026.

Summary

• Owen Hughes, a Director of C4 Therapeutics, Inc. (CCCC), was granted 35,500 stock options.
• The options have an exercise price of $1.44 per share.
• The grant date for these options was June 18, 2025.
• The options will vest in full upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, contingent on Mr. Hughes' continued service on the Board.
• The options expire on June 17, 2035.
• Following this transaction, Mr. Hughes beneficially owns 35,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's interests with shareholder value creation and serves as a retention mechanism. It indicates confidence in the company's future, though it doesn't reflect immediate financial performance.

Positives

• The grant of stock options to a director aligns management's interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• No immediate cash inflow for the company from this grant.
• Potential for future dilution if the stock options are exercised.

Risks

• The value of the options is dependent on the future stock price of C4 Therapeutics, Inc. exceeding the exercise price of $1.44.
• Vesting is subject to the director's continued service on the Board, meaning the options could be forfeited if the director leaves before vesting.

Future Outlook

The grant of long-term stock options to a director suggests a strategic intent to retain key leadership and align their interests with the company's long-term growth and shareholder value creation, contingent on continued service and future stock performance.

Industry Context

Insider equity grants, such as stock options, are a common practice in the biotechnology and pharmaceutical industries, like C4 Therapeutics, Inc., to attract, retain, and incentivize key talent, including directors, by linking their compensation to the company's stock performance and long-term success. This aligns with typical corporate governance practices for growth-oriented companies.

Comparison to Industry Standards

• The grant of 35,500 stock options to a director with a 10-year term and a vesting schedule tied to continued service is a standard practice for director compensation in the biotech sector.
• While specific comparable companies or projects are not mentioned in the filing, such grants are typical for companies of C4 Therapeutics' size and stage, aiming to align director incentives with shareholder value creation over a multi-year horizon.
• The exercise price of $1.44 would typically be the fair market value of the stock on the grant date, which is a standard practice for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of stockholders, subject to continued service.
• The director may choose to exercise the options at any point after vesting and before the expiration date of June 17, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stock Option, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Grant, Owen Hughes